Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free KPTI Stock Alerts

Karyopharm Therapeutics (KPTI) Financials

Karyopharm Therapeutics logo
$7.41 +0.32 (+4.51%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$7.40 -0.01 (-0.13%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Karyopharm Therapeutics

Annual Income Statements for Karyopharm Therapeutics

This table shows Karyopharm Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Consolidated Net Income / (Loss)		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Net Income / (Loss) Continuing Operations		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Total Pre-Tax Income 		-76 -118 -109 -178 -200 -196 -124 -165 -143 -76 -196
Total Operating Income		 -76 -119 -111 -180 -189 -172 -98 -142 -130 -119 -91
Total Gross Profit		 0.23 0.25 0.15 30 41 105 206 152 141 139 140
Total Revenue		 0.23 0.25 0.15 30 41 108 210 157 146 145 146
Operating Revenue		 0.23 0.25 0.15 30 41 108 210 157 146 145 146
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 2.71 3.40 5.21 4.94 6.01 5.95
Operating Cost of Revenue		 - - - - - 2.71 3.40 5.21 4.94 6.01 5.95
Total Operating Expenses		 76 119 111 210 230 277 305 294 271 259 231
Selling, General & Admin Expense		 16 22 24 49 108 126 144 145 132 115 105
Research & Development Expense		 60 98 87 161 122 151 161 149 139 143 126
Total Other Income / (Expense), net		 0.07 0.90 1.29 1.50 -10 -24 -26 -23 -13 43 -105
Interest Expense		 0.00 - 0.00 2.49 16 27 26 25 24 -7.28 108
Interest & Investment Income		 0.10 0.90 1.28 4.03 5.42 2.82 0.58 2.36 11 7.40 2.77
Other Income / (Expense), net		 -0.03 -0.00 0.01 -0.03 -0.05 0.21 -0.09 -0.08 -0.36 28 0.15
Income Tax Expense		 0.00 0.00 0.14 0.03 0.04 0.31 0.27 0.37 0.32 0.06 0.04
Basic Earnings per Share		 ($2.43) ($3.32) ($2.92) ($3.14) ($3.22) ($2.72) ($1.65) ($2.02) ($18.79) ($9.41) ($17.93)
Weighted Average Basic Shares Outstanding		 31.14M 35.62M 37.52M 56.78M 61.96M 72.04M 75.22M 81.87M 7.62M 8.13M 10.94M
Diluted Earnings per Share		 ($2.43) ($3.32) ($2.92) ($3.14) ($3.22) ($2.72) ($1.65) ($2.02) ($18.79) ($14.00) ($17.93)
Weighted Average Diluted Shares Outstanding		 31.14M 35.62M 37.52M 56.78M 61.96M 72.04M 75.22M 81.87M 7.62M 8.46K 10.94M
Weighted Average Basic & Diluted Shares Outstanding		 31.14M 35.62M 37.52M 56.78M 61.96M 72.04M 75.22M 113.34M 115.07M 126.24M 18.34M

Quarterly Income Statements for Karyopharm Therapeutics

This table shows Karyopharm Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -35 -42 -37 24 -32 -31 -23 -37 -33 -102 -22
Consolidated Net Income / (Loss)		 -35 -42 -37 24 -32 -31 -23 -37 -33 -102 -22
Net Income / (Loss) Continuing Operations		 -35 -42 -37 24 -32 -31 -23 -37 -33 -102 -22
Total Pre-Tax Income 		-34 -42 -37 24 -32 -31 -23 -37 -33 -102 -22
Total Operating Income		 -31 -38 -34 -28 -26 -31 -33 -24 -15 -18 -27
Total Gross Profit		 35 32 31 41 37 29 29 37 42 33 34
Total Revenue		 36 34 33 43 39 31 30 38 44 34 35
Operating Revenue		 36 34 33 43 39 31 30 38 44 34 35
Total Cost of Revenue		 0.91 1.49 1.91 1.47 1.30 1.33 1.30 1.05 2.11 1.48 1.35
Operating Cost of Revenue		 0.91 1.49 1.91 1.47 1.30 1.33 1.30 1.05 2.11 1.48 1.35
Total Operating Expenses		 66 70 65 69 64 60 62 61 57 50 60
Selling, General & Admin Expense		 31 31 30 31 28 27 27 28 27 23 27
Research & Development Expense		 36 39 35 38 36 33 35 33 31 28 34
Total Other Income / (Expense), net		 -3.23 -3.90 -3.53 52 -5.76 0.39 9.83 -13 -18 -84 4.37
Interest Expense		 6.07 6.21 5.88 -36 11 11 11 11 11 75 13
Interest & Investment Income		 2.75 2.52 2.16 1.93 1.83 1.48 1.00 0.61 0.55 0.61 0.51
Other Income / (Expense), net		 0.09 -0.21 0.20 14 3.79 10 20 -2.21 -7.42 -10 16
Income Tax Expense		 0.01 0.13 0.07 0.07 0.03 -0.11 0.04 0.04 0.03 -0.07 0.00
Basic Earnings per Share		 ($0.30) ($5.49) ($4.85) $2.26 ($3.85) ($0.20) ($2.77) ($4.32) ($3.82) ($9.35) ($1.02)
Weighted Average Basic Shares Outstanding		 114.40M 7.62M 7.70M 8.07K 8.34M 121.86M 8.47M 8.62M 8.67M 10.94M 22.01M
Diluted Earnings per Share		 ($0.30) ($5.49) ($4.85) ($2.97) ($3.85) ($0.15) ($2.77) ($4.32) ($3.82) ($9.35) ($1.24)
Weighted Average Diluted Shares Outstanding		 114.40M 7.62M 7.70M 10.30K 8.34M 126.81K 8.47M 8.62M 8.67M 10.94M 24.72K
Weighted Average Basic & Diluted Shares Outstanding		 114.53M 115.07M 117.71M 124.68M 125.31M 126.24M 8.64M 8.67M 17.05B 18.34M 22.66M

Annual Cash Flow Statements for Karyopharm Therapeutics

This table details how cash moves in and out of Karyopharm Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -5.37 -92 -8.70 49 12 -42 108 -61 -84 9.62 -1.94
Net Cash From Operating Activities		 -51 -94 -84 -159 -191 -160 -107 -150 -93 -127 -75
Net Cash From Continuing Operating Activities		 -51 -94 -84 -159 -191 -160 -107 -150 -93 -127 -75
Net Income / (Loss) Continuing Operations		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Consolidated Net Income / (Loss)		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Depreciation Expense		 0.32 0.63 0.72 0.74 0.97 0.97 0.79 0.62 0.53 0.34 0.30
Amortization Expense		 0.00 1.78 1.20 1.45 5.81 9.49 2.34 -0.01 -3.28 3.87 10
Non-Cash Adjustments To Reconcile Net Income		 14 18 22 17 16 25 38 37 24 -57 83
Changes in Operating Assets and Liabilities, net		 9.72 4.00 0.99 -0.17 -14 0.10 -25 -22 29 1.31 27
Net Cash From Investing Activities		 -67 -91 25 -108 78 -54 142 -104 7.94 95 43
Net Cash From Continuing Investing Activities		 -67 -91 25 -108 78 -54 142 -104 7.94 95 43
Purchase of Property, Plant & Equipment		 -2.83 -1.42 -0.07 -2.36 -0.21 -0.15 -0.21 -0.12 0.00 -0.14 0.00
Purchase of Investments		 -64 -305 -135 -243 -178 -275 -45 -226 -159 -59 0.00
Sale and/or Maturity of Investments		 0.00 216 159 138 257 221 193 122 167 154 43
Net Cash From Financing Activities		 113 93 51 316 124 172 74 194 1.12 42 30
Net Cash From Continuing Financing Activities		 113 93 51 316 124 172 74 194 1.12 42 30
Repayment of Debt		 - - - - - - - 0.00 0.00 0.00 -0.25
Repurchase of Common Equity		 - - - - - - - - 0.00 -2.59 -6.46
Issuance of Debt		 - - 0.00 167 - - - 0.00 0.00 83 27
Issuance of Common Equity		 113 93 51 149 51 172 14 194 1.12 1.45 9.51
Other Financing Activities, net		 0.00 0.00 0.04 0.00 74 0.00 60 0.00 0.00 -41 0.00
Cash Interest Paid		 - - - 0.00 0.00 11 16 34 21 39 11

Quarterly Cash Flow Statements for Karyopharm Therapeutics

This table details how cash moves in and out of Karyopharm Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -37 8.61 -22 54 -12 -10 -24 -0.05 -1.05 23 30
Net Cash From Operating Activities		 -30 -19 -44 -38 -19 -26 -39 -19 -5.86 -12 -23
Net Cash From Continuing Operating Activities		 -30 -19 -44 -38 -19 -26 -39 -19 -5.86 -12 -23
Net Income / (Loss) Continuing Operations		 -35 -42 -37 24 -32 -31 -23 -37 -33 -102 -22
Consolidated Net Income / (Loss)		 -35 -42 -37 24 -32 -31 -23 -37 -33 -102 -22
Depreciation Expense		 0.08 0.08 0.09 0.09 0.08 0.08 0.08 0.08 0.12 0.02 0.01
Amortization Expense		 -0.73 -0.80 -0.70 0.73 1.88 1.97 2.34 2.60 2.76 2.44 2.36
Non-Cash Adjustments To Reconcile Net Income		 5.58 5.70 5.51 -53 0.77 -9.78 -16 6.22 11 83 -6.42
Changes in Operating Assets and Liabilities, net		 0.05 18 -11 -10 9.89 13 -1.93 9.65 14 5.37 3.71
Net Cash From Investing Activities		 -7.69 27 22 51 7.47 15 15 18 4.81 5.00 3.20
Net Cash From Continuing Investing Activities		 -7.69 27 22 51 7.47 15 15 18 4.81 5.00 3.20
Sale and/or Maturity of Investments		 38 43 54 56 28 16 15 18 4.81 5.00 3.20
Net Cash From Financing Activities		 - 0.26 0.00 41 - 0.68 0.00 0.36 - 30 50
Net Cash From Continuing Financing Activities		 - 0.26 0.00 41 - 0.68 0.00 0.36 - 30 50
Repurchase of Common Equity		 - - - - - - 0.00 - - - -0.43
Issuance of Common Equity		 - 0.26 - - - 0.68 0.00 - - 9.16 50
Effect of Exchange Rate Changes		 - - -0.02 -0.01 0.04 -0.02 0.01 0.01 0.00 - 0.00
Cash Interest Paid		 4.03 6.42 0.00 19 11 8.20 7.26 7.12 - -3.71 0.00

Annual Balance Sheets for Karyopharm Therapeutics

This table presents Karyopharm Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 220 215 180 180 295 313 305 358 240 164 108
Total Current Assets		 208 178 132 148 279 277 276 350 234 156 103
Cash & Equivalents		 151 58 50 69 129 86 190 135 52 62 61
Short-Term Investments		 55 117 80 77 133 163 38 143 139 46 3.20
Accounts Receivable		 - - - - 7.86 13 22 47 27 31 26
Inventories, net		 - - - - 0.35 2.64 4.11 4.22 3.04 4.74 4.04
Prepaid Expenses		 2.03 1.97 2.08 1.75 7.29 9.29 14 20 12 12 9.19
Plant, Property, & Equipment, net		 2.75 3.48 2.84 2.19 3.05 2.22 1.64 1.14 0.61 0.40 0.10
Total Noncurrent Assets		 9.83 34 46 30 13 34 28 6.87 5.91 7.56 5.17
Other Noncurrent Operating Assets		 0.77 - - - 11 9.36 27 6.24 5.61 7.22 4.82
Other Noncurrent Nonoperating Assets		 0.40 0.48 0.48 0.29 0.71 0.72 0.64 0.63 0.30 0.34 0.35
Total Liabilities & Shareholders' Equity		 220 215 180 180 295 313 305 358 240 164 108
Total Liabilities		 14 17 18 51 245 263 385 375 377 350 401
Total Current Liabilities		 12 15 16 49 46 60 74 66 69 92 92
Short-Term Debt		 - - - - - - - - - 0.00 21
Accounts Payable		 6.29 3.81 4.75 5.67 0.99 4.45 1.60 2.77 3.12 5.11 4.00
Accrued Expenses		 5.83 11 11 21 41 53 69 58 61 61 64
Other Current Liabilities		 0.06 0.10 0.08 0.13 2.15 2.53 2.99 4.72 4.96 27 2.55
Total Noncurrent Liabilities		 1.24 1.95 1.67 1.36 199 202 311 309 307 258 309
Long-Term Debt		 - - - 0.00 110 118 169 170 171 95 95
Other Noncurrent Operating Liabilities		 - - - - 87 84 142 139 136 164 214
Total Equity & Noncontrolling Interests		 207 198 162 129 50 51 -80 -17 -136 -186 -293
Total Preferred & Common Equity		 207 198 162 129 50 51 -80 -17 -136 -186 -293
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 207 198 162 129 50 51 -80 -17 -136 -186 -293
Common Stock		 345 455 529 625 923 1,120 1,099 1,328 1,351 1,378 1,467
Retained Earnings		 -138 -257 -366 -495 -873 -1,070 -1,179 -1,344 -1,487 -1,563 -1,759
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.28 -0.27 -0.22 -0.04 0.52 0.19 -0.64 -0.16 -0.36 0.07

Quarterly Balance Sheets for Karyopharm Therapeutics

This table presents Karyopharm Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 270 204 214 189 128 105 96 131
Total Current Assets		 263 198 209 185 120 98 90 126
Cash & Equivalents		 44 31 85 73 39 39 38 91
Short-Term Investments		 165 118 67 61 31 13 8.21 0.00
Accounts Receivable		 38 31 38 32 35 33 32 23
Inventories, net		 3.11 2.77 3.48 4.67 4.77 4.99 3.97 3.60
Prepaid Expenses		 13 15 15 15 10 8.25 8.03 8.53
Plant, Property, & Equipment, net		 0.69 0.72 0.63 0.50 0.32 0.24 0.12 0.09
Total Noncurrent Assets		 6.05 5.37 4.81 4.23 7.15 6.77 6.36 4.99
Other Noncurrent Operating Assets		 5.67 5.07 4.51 3.92 6.81 6.42 6.01 4.68
Other Noncurrent Nonoperating Assets		 0.38 0.30 0.30 0.31 0.34 0.35 0.35 0.32
Total Liabilities & Shareholders' Equity		 270 204 214 189 128 105 96 131
Total Liabilities		 370 373 346 349 334 344 365 397
Total Current Liabilities		 62 65 58 61 90 99 87 117
Short-Term Debt		 - - - - - 6.25 13 32
Accounts Payable		 0.94 5.03 2.80 5.78 5.87 2.60 5.39 4.28
Accrued Expenses		 56 55 50 50 57 63 66 76
Other Current Liabilities		 5.42 5.46 5.01 5.61 27 27 2.94 4.49
Total Noncurrent Liabilities		 308 308 288 288 243 245 278 280
Long-Term Debt		 171 171 118 94 95 90 108 106
Other Noncurrent Operating Liabilities		 138 137 171 194 148 155 170 174
Total Equity & Noncontrolling Interests		 -100 -169 -132 -160 -206 -239 -269 -266
Total Preferred & Common Equity		 -100 -169 -132 -160 -206 -239 -269 -266
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -100 -169 -132 -160 -206 -239 -269 -266
Common Stock		 1,346 1,356 1,369 1,373 1,381 1,385 1,388 1,516
Retained Earnings		 -1,445 -1,524 -1,501 -1,533 -1,587 -1,624 -1,657 -1,782
Accumulated Other Comprehensive Income / (Loss)		 -0.74 -0.52 -0.61 -0.22 -0.32 -0.25 -0.26 0.04

Annual Metrics And Ratios for Karyopharm Therapeutics

This table displays calculated financial ratios and metrics derived from Karyopharm Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9.17% -38.40% 942.21% 0.00% 34.80% 164.31% 94.12% -25.14% -7.03% -0.55% 0.57%
EBITDA Growth		 -54.43% 6.74% -18.30% -38.08% -2.71% 11.70% 40.92% -48.78% 6.37% 34.53% 7.73%
EBIT Growth		 -56.94% 7.02% -17.97% -37.74% -5.23% 9.34% 42.70% -44.66% 8.71% 29.91% 0.54%
NOPAT Growth		 -57.00% 7.01% -17.79% 3.59% -5.22% 9.21% 42.82% -44.70% 8.90% 7.79% 24.06%
Net Income Growth		 -55.96% 7.28% -17.71% 0.00% -11.87% 1.66% 36.78% -33.20% 13.43% 46.60% -156.52%
EPS Growth		 -36.63% 12.05% 3.77% 0.00% -2.55% 15.53% 39.34% -22.42% 13.43% 25.60% -28.07%
Operating Cash Flow Growth		 -82.77% 10.25% 12.65% 0.00% -19.93% 16.03% 33.15% -39.62% 38.00% -37.49% 40.88%
Free Cash Flow Firm Growth		 -72.75% 4.76% 11.30% -78.28% 84.77% -349.40% 73.80% -284.95% 50.38% 31.02% -7.40%
Invested Capital Growth		 -45.57% -13.71% -254.64% 100.00% 0.00% -1.90% -34.94% 13.54% -24.94% -27.12% -9.79%
Revenue Q/Q Growth		 3.73% 16.67% 1,260.17% 0.00% 0.00% 0.00% 76.84% -37.11% 0.11% -2.16% 2.48%
EBITDA Q/Q Growth		 -2.50% 1.87% -10.65% 0.00% -3,068.61% -1,820.38% 45.83% -133.43% -3.69% 18.43% -8.55%
EBIT Q/Q Growth		 -2.87% 1.90% -10.40% 0.00% 0.00% 0.00% 45.82% -129.79% -3.29% 15.62% -8.02%
NOPAT Q/Q Growth		 -2.90% 1.89% -10.26% 0.00% 0.00% 0.00% 46.09% -131.71% -3.14% 5.18% 12.90%
Net Income Q/Q Growth		 -2.71% 1.89% -10.36% 0.00% 0.00% 0.00% 39.83% -87.69% -2.38% 12.64% -57.31%
EPS Q/Q Growth		 0.00% 5.50% -6.44% 0.00% 0.00% 0.00% 40.00% -87.04% -2.38% 18.42% -24.69%
Operating Cash Flow Q/Q Growth		 -8.80% 0.44% 16.40% 0.00% 4.35% 5.24% 34.38% -53.81% 8.18% -6.01% 15.65%
Free Cash Flow Firm Q/Q Growth		 0.00% 3.42% 12.03% -851.61% -142.99% -5,432.87% 53.13% -34.62% 14.77% -47.37% 43.38%
Invested Capital Q/Q Growth		 -21.63% -32.74% -157.42% 100.00% -3.65% -3.38% 12.13% -4.77% -13.50% -0.53% -12.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 97.50% 98.38% 96.68% 96.62% 95.86% 95.93%
EBITDA Margin		 -46,666.40% -70,653.25% -8,019.88% -585.88% -446.38% -149.13% -45.39% -90.20% -90.84% -59.79% -54.85%
Operating Margin		 -47,630.40% -71,903.90% -8,133.21% -592.97% -462.85% -159.00% -46.84% -90.53% -88.71% -82.24% -62.10%
EBIT Margin		 -47,631.20% -71,897.40% -8,138.26% -593.08% -462.98% -158.80% -46.88% -90.58% -88.95% -62.69% -62.00%
Profit (Net Income) Margin		 -47,272.40% -71,153.90% -8,036.39% -588.10% -488.08% -181.59% -59.14% -105.23% -97.99% -52.62% -134.21%
Tax Burden Percent		 100.00% 100.13% 100.05% 100.01% 100.02% 100.16% 100.22% 100.22% 100.23% 100.07% 100.02%
Interest Burden Percent		 99.25% 98.84% 98.70% 99.15% 105.40% 114.17% 125.89% 115.91% 109.92% 83.88% 216.44%
Effective Tax Rate		 0.00% 0.00% -0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -58.34% -60.77% -88.43% -275.61% -801.99% -391.29% 852.05% 343.18% 187.23% 47.43% 81.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -54.65% -55.94% -72.43% -199.58% -128.37% -56.46% -31.81% -42.89% -43.40% -44.98% -66.38%
Return on Assets (ROA)		 -54.24% -55.37% -71.52% -197.91% -135.33% -64.56% -40.13% -49.83% -47.81% -37.75% -143.71%
Return on Common Equity (ROCE)		 -58.34% -60.77% -88.43% -275.61% -801.99% -391.29% 852.05% 343.18% 187.23% 47.43% 81.86%
Return on Equity Simple (ROE_SIMPLE)		 -59.58% -67.54% -99.63% 0.00% -400.99% -388.31% 155.75% 992.38% 0.00% 41.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 -83 -78 -131 -126 -132 -120 -69 -100 -91 -84 -63
NOPAT Margin		 -33,341.28% -50,332.73% -8,137.18% -415.08% -324.00% -111.30% -32.79% -63.37% -62.09% -57.57% -43.47%
Net Nonoperating Expense Percent (NNEP)		 -16.40% -16.64% 0.92% -59.53% -86.05% -48.29% -49.15% -74.77% -80.01% 40.01% 454.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -64.87% -261.22% 91.46% 40.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2.50% 1.62% 3.32% 3.38% 4.14% 4.07%
SG&A Expenses to Revenue		 8,632.80% 15,550.65% 1,549.53% 161.02% 263.68% 116.96% 68.56% 92.57% 90.31% 79.48% 72.03%
R&D to Revenue		 39,097.60% 56,453.25% 6,683.68% 531.95% 299.17% 139.53% 76.66% 94.64% 95.01% 98.62% 86.00%
Operating Expenses to Revenue		 47,730.40% 72,003.90% 8,233.21% 692.97% 562.85% 256.49% 145.21% 187.21% 185.32% 178.10% 158.03%
Earnings before Interest and Taxes (EBIT)		 -119 -111 -131 -180 -189 -172 -98 -142 -130 -91 -91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -117 -109 -129 -178 -183 -161 -95 -142 -133 -87 -80
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.39 2.39 3.40 0.00 24.18 22.54 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.39 2.39 3.40 0.00 24.18 22.54 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1,893.81 2,517.46 274.54 18.75 29.44 10.54 2.32 1.76 0.68 0.58 859.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% -29.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,055.76 1,381.18 164.84 18.75 25.64 9.08 2.00 1.06 0.53 0.49 859.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 2.21 2.33 -2.12 -10.21 -1.25 -0.51 -0.47
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 2.21 2.33 -2.12 -10.21 -1.25 -0.51 -0.40
Financial Leverage		 -1.05 -1.07 -1.21 -1.36 -3.13 -3.14 7.73 1.83 0.86 0.11 -0.12
Leverage Ratio		 1.08 1.10 1.24 1.39 5.93 6.06 -21.23 -6.89 -3.92 -1.26 -0.57
Compound Leverage Factor		 1.07 1.08 1.22 1.38 6.25 6.92 -26.73 -7.98 -4.30 -1.05 -1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 68.82% 70.00% 188.90% 110.85% 492.38% -103.49% -87.77%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.47%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 68.82% 70.00% 188.90% 110.85% 492.38% -103.49% -74.30%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 0.00% 31.18% 30.00% -88.90% -10.85% -392.38% 203.49% 187.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.60 -0.73 -1.78 -1.20 -1.29 -1.09 -1.71
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.85 0.98 0.69 0.77 0.16 0.16 -0.91
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.60 -0.73 -1.78 -1.20 -1.29 -1.09 -1.45
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.83 -0.98 -2.46 -1.71 -1.88 -1.13 -2.16
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 1.17 1.31 0.95 1.09 0.23 0.17 -1.15
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.83 -0.98 -2.46 -1.71 -1.88 -1.13 -1.83
Altman Z-Score		 14.05 8.72 -0.37 0.00 -2.23 -2.81 -4.23 -4.73 -8.86 -13.64 163.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.74 7.99 3.00 0.00 6.01 4.59 3.74 5.31 3.37 1.70 1.12
Quick Ratio		 11.61 7.86 2.96 0.00 5.82 4.35 3.41 4.93 3.14 1.51 0.98
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -80 -76 -97 -173 -26 -118 -31 -119 -59 -41 -44
Operating Cash Flow to CapEx		 -6,640.47% -120,558.57% -118,898.39% -6,733.69% -92,632.04% -110,506.21% -50,526.42% -126,740.68% 0.00% -89,778.87% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -69.32 -1.68 -4.36 -1.19 -4.77 -2.49 0.00 -0.41
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -63.83 -12.20 -5.90 -4.11 -5.98 -3.89 0.00 -0.70
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -64.77 -12.21 -5.91 -4.12 -5.99 -3.89 0.00 -0.70
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.34 0.28 0.36 0.68 0.47 0.49 0.72 1.07
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 10.42 11.86 4.51 3.94 5.03 5.13
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 1.81 1.01 1.25 1.36 1.54 1.36
Fixed Asset Turnover		 0.08 0.05 0.64 0.00 0.00 41.06 108.69 112.96 167.37 288.74 579.63
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 1.00 1.12 2.38 1.68 1.46 1.31
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 35.02 30.77 80.85 92.54 72.54 71.15
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 201.73 362.10 291.62 268.36 236.43 269.26
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 366.69 324.71 153.20 217.73 250.04 279.47
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -129.93 68.16 219.27 143.17 58.93 60.93
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 -13 -47 0.00 -106 -108 -146 -126 -158 -200 -220
Invested Capital Turnover		 -0.03 -0.01 -0.05 -1.29 -0.77 -1.01 -1.65 -1.15 -1.03 -0.81 -0.69
Increase / (Decrease) in Invested Capital		 -3.64 -1.59 -34 47 -106 -2.01 -38 20 -31 -43 -20
Enterprise Value (EV)		 264 213 265 569 1,048 981 420 167 78 71 125,568
Market Capitalization		 473 388 441 569 1,204 1,139 486 276 99 85 125,494
Book Value per Share		 $5.55 $3.93 $2.82 $0.00 $0.79 $0.69 ($1.05) ($0.21) ($1.19) ($1.48) ($0.02)
Tangible Book Value per Share		 $5.55 $3.93 $2.82 $0.00 $0.79 $0.69 ($1.05) ($0.21) ($1.19) ($1.48) ($0.02)
Total Capital		 198 162 129 0.00 160 168 90 153 35 -91 -156
Total Debt		 0.00 0.00 0.00 0.00 110 118 169 170 171 95 137
Total Long-Term Debt		 0.00 0.00 0.00 0.00 110 118 169 170 171 95 116
Net Debt		 -210 -175 -176 0.00 -155 -158 -66 -109 -21 -14 73
Capital Expenditures (CapEx)		 1.42 0.07 0.06 2.36 0.21 0.15 0.21 0.12 0.00 0.14 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -14 -48 0.00 -31 -35 -33 5.22 -28 -45 -32
Debt-free Net Working Capital (DFNWC)		 162 115 99 0.00 232 216 202 284 164 64 32
Net Working Capital (NWC)		 162 115 99 0.00 232 216 202 284 164 64 11
Net Nonoperating Expense (NNE)		 35 32 -1.62 52 67 76 55 66 52 -7.19 133
Net Nonoperating Obligations (NNO)		 -210 -175 -176 0.00 -156 -159 -66 -110 -21 -14 73
Total Depreciation and Amortization (D&A)		 2.41 1.92 1.90 2.18 6.79 10 3.13 0.61 -2.75 4.21 10
Debt-free, Cash-free Net Working Capital to Revenue		 -5,266.00% -9,345.45% -2,972.77% 0.00% -75.45% -32.75% -15.76% 3.33% -18.94% -30.65% -21.67%
Debt-free Net Working Capital to Revenue		 64,987.20% 74,779.22% 6,165.48% 0.00% 567.87% 200.15% 96.22% 180.97% 112.61% 44.22% 21.97%
Net Working Capital to Revenue		 64,987.20% 74,779.22% 6,165.48% 0.00% 567.87% 200.15% 96.22% 180.97% 112.61% 44.22% 7.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.32) ($2.92) ($2.81) ($3.14) $0.00 ($2.72) ($1.65) ($2.02) ($18.75) ($0.63) ($17.93)
Adjusted Weighted Average Basic Shares Outstanding		 35.88M 41.90M 45.90M 60.86M 0.00 74.63M 79.16M 81.87M 7.61M 121.86M 10.94M
Adjusted Diluted Earnings per Share		 ($3.32) ($2.92) ($2.81) ($3.14) $0.00 ($2.72) ($1.65) ($2.02) ($18.75) ($0.93) ($17.93)
Adjusted Weighted Average Diluted Shares Outstanding		 35.88M 41.90M 45.90M 60.86M 0.00 74.63M 79.16M 81.87M 7.61M 126.81K 10.94M
Adjusted Basic & Diluted Earnings per Share		 ($3.32) ($2.92) ($2.81) ($3.14) $0.00 ($2.72) ($1.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.62M 37.52M 45.90M 56.80M 0.00 72.04M 75.22M 113.34M 7.67M 126.24M 18.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -83 -78 -91 -126 -132 -120 -69 -100 -91 -84 -63
Normalized NOPAT Margin		 -33,341.28% -50,332.73% -5,693.25% -415.08% -324.00% -111.30% -32.79% -63.37% -62.09% -57.57% -43.47%
Pre Tax Income Margin		 -47,272.40% -71,063.64% -8,032.46% -588.02% -487.98% -181.31% -59.01% -105.00% -97.77% -52.58% -134.18%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -72.17 -12.10 -6.32 -3.78 -5.69 -5.45 0.00 -0.84
NOPAT to Interest Expense		 0.00 0.00 0.00 -50.51 -8.47 -4.43 -2.64 -3.98 -3.81 0.00 -0.59
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -73.12 -12.11 -6.33 -3.78 -5.70 -5.45 0.00 -0.84
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -51.46 -8.48 -4.44 -2.65 -3.99 -3.81 0.00 -0.59
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.30%

Quarterly Metrics And Ratios for Karyopharm Therapeutics

This table displays calculated financial ratios and metrics derived from Karyopharm Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 114,354,540.00 114,533,991.00 115,067,083.00 117,710,263.00 124,683,681.00 - 126,240,054.00 8,639,904.00 8,671,278.00 - 18,343,968.00
DEI Adjusted Shares Outstanding		 7,623,636.00 7,635,599.00 7,671,139.00 7,847,351.00 8,312,245.00 - 8,416,004.00 8,639,904.00 8,671,278.00 - 18,343,968.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.53 -5.48 -4.87 3.03 -3.86 - -2.79 -4.31 -3.82 - -1.22
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -0.38% 0.50% -14.40% 13.86% 7.70% -9.50% -9.39% -11.35% 13.57% 11.58% 16.83%
EBITDA Growth		 -3.56% -13.88% -7.49% 57.05% 35.48% 50.65% 67.77% -83.91% 3.79% -33.01% 27.63%
EBIT Growth		 -1.13% -12.21% -7.70% 53.21% 27.85% 44.33% 59.98% -92.40% -0.65% -31.75% 22.95%
NOPAT Growth		 -1.37% -11.63% -9.26% -35.46% 15.92% 17.26% 1.49% 39.12% 42.09% 42.96% 19.53%
Net Income Growth		 5.01% -8.65% -9.48% 172.91% 7.05% 26.43% 37.20% -256.57% -3.29% -232.03% 4.56%
EPS Growth		 33.33% -8.65% -9.48% 172.91% 7.05% 58.33% 42.89% -45.45% 0.78% -146.70% 55.23%
Operating Cash Flow Growth		 -4.09% 30.76% -131.23% -49.81% 34.12% -38.88% 10.84% 51.43% 69.88% 54.17% 41.70%
Free Cash Flow Firm Growth		 94.91% 111.53% -142.26% 114.21% 1,330.11% 316.66% 179.73% 5,235.18% -136.16% -65.78% 80.39%
Invested Capital Growth		 -15.32% -24.94% -7.63% -20.40% -43.52% -27.12% -22.97% -17.05% 2.29% -9.79% -20.84%
Revenue Q/Q Growth		 -4.18% -6.28% -1.84% 29.16% -9.36% -21.25% -1.73% 26.37% 16.12% -22.63% 2.90%
EBITDA Q/Q Growth		 -5.08% -21.76% 11.78% 61.95% -57.87% 6.87% 42.38% -117.11% 17.41% -28.75% 68.65%
EBIT Q/Q Growth		 -5.51% -21.97% 11.72% 58.81% -62.70% 5.89% 36.54% -98.01% 14.89% -23.19% 62.89%
NOPAT Q/Q Growth		 -5.70% -20.95% 10.71% -18.66% 34.39% -19.02% -6.31% 26.67% 37.59% -17.24% -49.97%
Net Income Q/Q Growth		 -5.75% -21.25% 10.70% 163.68% -234.80% 4.03% 23.78% -58.78% 11.07% -208.50% 78.09%
EPS Q/Q Growth		 -3.45% -21.25% 10.70% 163.68% -234.80% 42.31% 26.91% -55.96% 11.57% -144.76% 86.74%
Operating Cash Flow Q/Q Growth		 -14.91% 37.06% -135.27% 11.95% 49.47% -32.68% -51.04% 52.04% 68.66% -101.84% -92.15%
Free Cash Flow Firm Q/Q Growth		 -128.14% 246.50% -363.34% 101.61% 19,654.32% -50.38% -49.61% 8.01% -233.89% 146.96% 165.63%
Invested Capital Q/Q Growth		 -0.34% -13.50% 6.67% -13.29% -19.60% -0.53% 9.73% -7.84% 0.16% -12.96% 0.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 97.47% 95.60% 94.23% 96.58% 96.65% 95.64% 95.67% 97.23% 95.20% 95.65% 96.16%
EBITDA Margin		 -88.37% -114.81% -103.18% -30.40% -52.94% -62.61% -36.71% -63.06% -44.85% -74.63% -22.74%
Operating Margin		 -86.81% -112.03% -101.91% -65.72% -67.77% -102.42% -110.80% -64.30% -34.56% -52.36% -76.31%
EBIT Margin		 -86.56% -112.66% -101.32% -32.31% -57.99% -69.30% -44.75% -70.12% -51.40% -81.83% -29.51%
Profit (Net Income) Margin		 -95.83% -123.97% -112.79% 55.61% -82.70% -100.78% -78.17% -98.22% -75.21% -299.89% -63.86%
Tax Burden Percent		 100.03% 100.31% 100.19% 99.72% 100.09% 99.65% 100.15% 100.11% 100.10% 99.93% 100.00%
Interest Burden Percent		 110.66% 109.70% 111.11% -172.59% 142.47% 145.93% 174.40% 139.91% 146.18% 366.70% 216.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 116.15% 187.23% 136.68% 88.42% 67.28% 47.43% 33.36% 66.60% 58.11% 81.86% 82.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -50.39% -54.97% -53.68% -18.39% -37.47% -49.72% -38.30% -60.38% -51.28% -87.62% -34.42%
Return on Assets (ROA)		 -55.78% -60.49% -59.75% 31.65% -53.44% -72.31% -66.89% -84.56% -75.04% -321.10% -74.48%
Return on Common Equity (ROCE)		 116.15% 187.23% 136.68% 88.42% 67.28% 47.43% 33.36% 66.60% 58.11% 81.86% 82.70%
Return on Equity Simple (ROE_SIMPLE)		 139.22% 0.00% 86.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -22 -26 -24 -28 -18 -22 -23 -17 -11 -12 -19
NOPAT Margin		 -60.77% -78.42% -71.34% -65.54% -47.44% -71.69% -77.56% -45.01% -24.19% -36.65% -53.42%
Net Nonoperating Expense Percent (NNEP)		 -134.79% -23.46% -39.36% 101.83% -34.93% -49.45% 0.78% 439.44% 129.68% 307.32% 10.18%
Return On Investment Capital (ROIC_SIMPLE)		 - -76.24% -1,088.00% 196.59% 28.07% 23.95% 21.03% 11.93% 7.17% 8.01% 14.69%
Cost of Revenue to Revenue		 2.53% 4.40% 5.77% 3.42% 3.35% 4.36% 4.33% 2.77% 4.80% 4.35% 3.84%
SG&A Expenses to Revenue		 85.55% 90.94% 89.20% 72.62% 71.25% 89.02% 91.13% 75.08% 60.41% 66.82% 76.10%
R&D to Revenue		 98.73% 116.69% 106.94% 89.68% 93.17% 109.04% 115.34% 86.45% 69.35% 81.18% 96.38%
Operating Expenses to Revenue		 184.28% 207.63% 196.14% 162.30% 164.42% 198.06% 206.46% 161.53% 129.76% 148.01% 172.48%
Earnings before Interest and Taxes (EBIT)		 -31 -38 -34 -14 -22 -21 -13 -27 -23 -28 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -39 -34 -13 -21 -19 -11 -24 -20 -25 -7.97
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.05 0.68 1.24 0.70 0.70 0.58 0.22 0.27 0.40 859.16 0.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.79 0.53 1.39 0.47 0.43 0.49 0.40 0.59 0.92 859.66 0.99
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.70 -1.25 -1.01 -0.89 -0.59 -0.51 -0.46 -0.40 -0.45 -0.47 -0.52
Long-Term Debt to Equity		 -1.70 -1.25 -1.01 -0.89 -0.59 -0.51 -0.46 -0.37 -0.40 -0.40 -0.40
Financial Leverage		 0.08 0.86 0.33 0.50 0.30 0.11 -0.12 -0.02 -0.08 -0.12 -0.15
Leverage Ratio		 -2.08 -3.92 -2.48 -2.52 -1.77 -1.26 -0.89 -0.86 -0.67 -0.57 -0.55
Compound Leverage Factor		 -2.30 -4.30 -2.75 4.34 -2.52 -1.83 -1.55 -1.20 -0.97 -2.09 -1.19
Debt to Total Capital		 242.80% 492.38% 7,878.78% -826.39% -143.59% -103.49% -86.01% -66.95% -81.18% -87.77% -108.33%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.37% -8.41% -13.47% -25.28%
Long-Term Debt to Total Capital		 242.80% 492.38% 7,878.78% -826.39% -143.59% -103.49% -86.01% -62.59% -72.76% -74.30% -83.06%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -142.80% -392.38% -7,778.78% 926.39% 243.59% 203.49% 186.01% 166.95% 181.18% 187.77% 208.33%
Debt to EBITDA		 -1.33 -1.29 -1.27 -1.00 -0.88 -1.09 -1.50 -1.28 -1.63 -1.71 -1.79
Net Debt to EBITDA		 0.30 0.16 -0.16 0.29 0.37 0.16 -0.40 -0.59 -1.01 -0.91 -0.61
Long-Term Debt to EBITDA		 -1.33 -1.29 -1.27 -1.00 -0.88 -1.09 -1.50 -1.20 -1.47 -1.45 -1.37
Debt to NOPAT		 -1.94 -1.88 -1.85 -1.29 -1.07 -1.13 -1.14 -1.19 -1.65 -2.16 -2.34
Net Debt to NOPAT		 0.43 0.23 -0.24 0.37 0.45 0.17 -0.30 -0.55 -1.03 -1.15 -0.80
Long-Term Debt to NOPAT		 -1.94 -1.88 -1.85 -1.29 -1.07 -1.13 -1.14 -1.11 -1.48 -1.83 -1.80
Altman Z-Score		 -6.19 -7.59 -9.23 -8.33 -9.97 -12.24 -16.29 -21.16 -23.28 165.51 -17.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.24 3.37 3.04 3.62 3.00 1.70 1.33 0.99 1.03 1.12 1.08
Quick Ratio		 3.97 3.14 2.75 3.30 2.69 1.51 1.16 0.85 0.89 0.98 0.97
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.42 5.01 -13 0.21 42 21 11 11 -15 7.14 19
Operating Cash Flow to CapEx		 0.00% 0.00% -22,423.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -0.56 0.81 -2.24 0.00 3.70 1.86 0.96 1.01 -1.38 0.10 1.51
Operating Cash Flow to Interest Expense		 -4.86 -2.99 -7.43 0.00 -1.71 -2.30 -3.55 -1.67 -0.53 -0.16 -1.81
Operating Cash Flow Less CapEx to Interest Expense		 -4.86 -2.99 -7.46 0.00 -1.71 -2.30 -3.55 -1.67 -0.53 -0.16 -1.81
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.58 0.49 0.53 0.57 0.65 0.72 0.86 0.86 1.00 1.07 1.17
Accounts Receivable Turnover		 4.46 3.94 4.24 4.15 4.26 5.03 4.29 3.87 4.48 5.13 5.16
Inventory Turnover		 1.45 1.36 1.67 1.62 1.58 1.54 1.43 1.18 1.34 1.36 1.43
Fixed Asset Turnover		 150.53 167.37 179.16 208.99 251.38 288.74 273.06 314.84 462.01 579.63 731.81
Accounts Payable Turnover		 6.06 1.68 0.78 2.27 1.83 1.46 0.99 1.85 1.04 1.31 1.18
Days Sales Outstanding (DSO)		 81.79 92.54 86.12 88.04 85.69 72.54 85.17 94.30 81.51 71.15 70.77
Days Inventory Outstanding (DIO)		 252.09 268.36 218.79 225.97 230.33 236.43 254.90 310.14 271.99 269.26 254.82
Days Payable Outstanding (DPO)		 60.19 217.73 466.80 160.72 199.20 250.04 368.58 197.55 351.87 279.47 309.12
Cash Conversion Cycle (CCC)		 273.68 143.17 -161.89 153.29 116.82 58.93 -28.52 206.88 1.62 60.93 16.47
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -139 -158 -147 -167 -199 -200 -181 -195 -195 -220 -219
Invested Capital Turnover		 -1.12 -1.03 -0.99 -0.95 -0.88 -0.81 -0.87 -0.76 -0.72 -0.69 -0.76
Increase / (Decrease) in Invested Capital		 -18 -31 -10 -28 -60 -43 -34 -28 4.56 -20 -38
Enterprise Value (EV)		 115 78 196 68 64 71 57 81 131 125,568 149
Market Capitalization		 153 99 174 102 103 85 31 37 57 125,494 102
Book Value per Share		 ($0.88) ($1.19) ($1.47) ($1.12) ($1.28) ($1.48) ($1.63) ($27.65) ($31.05) ($0.02) ($14.48)
Tangible Book Value per Share		 ($0.88) ($1.19) ($1.47) ($1.12) ($1.28) ($1.48) ($1.63) ($27.65) ($31.05) ($0.02) ($14.48)
Total Capital		 70 35 2.17 -14 -66 -91 -111 -143 -149 -156 -128
Total Debt		 171 171 171 118 94 95 95 96 121 137 138
Total Long-Term Debt		 171 171 171 118 94 95 95 90 108 116 106
Net Debt		 -38 -21 22 -34 -39 -14 25 44 75 73 47
Capital Expenditures (CapEx)		 0.00 0.00 0.20 0.00 0.00 -0.05 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.72 -28 -16 -1.24 -10 -45 -40 -47 -31 -32 -50
Debt-free Net Working Capital (DFNWC)		 201 164 133 151 123 64 30 4.90 15 32 41
Net Working Capital (NWC)		 201 164 133 151 123 64 30 -1.35 2.59 11 9.03
Net Nonoperating Expense (NNE)		 13 15 14 -52 14 8.88 0.18 20 22 90 3.66
Net Nonoperating Obligations (NNO)		 -39 -21 22 -35 -40 -14 25 44 74 73 47
Total Depreciation and Amortization (D&A)		 -0.65 -0.73 -0.62 0.82 1.96 2.05 2.42 2.68 2.88 2.46 2.38
Debt-free, Cash-free Net Working Capital to Revenue		 -5.29% -18.94% -11.40% -0.85% -6.94% -30.65% -28.20% -34.09% -21.60% -21.67% -32.81%
Debt-free Net Working Capital to Revenue		 137.90% 112.61% 94.71% 103.61% 83.04% 44.22% 21.02% 3.57% 10.59% 21.97% 27.31%
Net Working Capital to Revenue		 137.90% 112.61% 94.71% 103.61% 83.04% 44.22% 21.02% -0.98% 1.82% 7.59% 5.98%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) ($82.35) ($4.80) $2.25 ($3.90) ($0.20) ($2.77) ($4.32) ($3.82) ($9.35) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding		 114.40M 507.73K 7.70M 8.07M 8.33M 121.86M 8.47M 8.62M 8.67M 10.94M 22.01M
Adjusted Diluted Earnings per Share		 ($0.30) ($82.35) ($4.80) ($3.00) ($3.90) ($0.15) ($2.77) ($4.32) ($3.82) ($9.35) ($1.24)
Adjusted Weighted Average Diluted Shares Outstanding		 114.40M 507.73K 7.70M 10.30M 8.33M 126.81K 8.47M 8.62M 8.67M 10.94M 24.72K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($82.35) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($9.35) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 114.53M 7.67M 7.85M 8.31M 8.35M 126.24M 8.64M 8.67M 17.05B 18.34M 22.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -26 -24 -28 -18 -22 -23 -17 -11 -12 -19
Normalized NOPAT Margin		 -60.77% -78.42% -71.34% -65.54% -47.44% -71.69% -77.56% -45.01% -24.19% -36.65% -53.42%
Pre Tax Income Margin		 -95.79% -123.59% -112.57% 55.76% -82.62% -101.14% -78.05% -98.11% -75.14% -300.08% -63.85%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.13 -6.12 -5.70 0.00 -1.98 -1.89 -1.22 -2.37 -2.06 -0.37 -0.82
NOPAT to Interest Expense		 -3.60 -4.26 -4.02 0.00 -1.62 -1.95 -2.12 -1.52 -0.97 -0.17 -1.49
EBIT Less CapEx to Interest Expense		 -5.13 -6.12 -5.74 0.00 -1.98 -1.88 -1.22 -2.37 -2.06 -0.37 -0.82
NOPAT Less CapEx to Interest Expense		 -3.60 -4.26 -4.05 0.00 -1.62 -1.95 -2.12 -1.52 -0.97 -0.17 -1.49
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.30% -3.54%

Financials Breakdown Chart

Key Financial Trends

Karyopharm Therapeutics (NASDAQ: KPTI) remains a highly cash-consuming biotech with meaningful revenue growth in Q1 2026, but losses and a strained balance sheet still define the story.

In the latest quarter, revenue rose to $35.1 million from $34.1 million in Q4 2025 and $30.0 million in Q1 2025. Gross profit also improved modestly, while operating revenue has now shown a clearer upward trend versus last year. That said, operating expenses remain far above gross profit, so the company is still posting substantial operating losses.

Quarterly trend check: Q1 2026 net loss was $22.4 million, an improvement from $102.2 million in Q4 2025, though Q4 included a much larger interest expense burden. Compared with Q1 2025, the loss also narrowed modestly from $23.5 million. Cash from operations remained negative at -$22.7 million, but the company offset that with a large equity raise and modest investment sales, ending the quarter with $90.9 million in cash and equivalents.

  • Revenue is moving in the right direction: Q1 2026 revenue of $35.1 million was above both Q4 2025 and Q1 2025 levels.
  • Gross profit remains strong: Q1 2026 gross profit of $33.7 million still covered a large portion of operating costs.
  • Cash balance improved sharply: Cash and equivalents rose to $90.9 million from $37.7 million in Q3 2025 and $38.8 million in Q1 2025.
  • Liquidity was boosted by financing: The company raised $50.2 million from common equity in Q1 2026.
  • Net cash increased in the quarter: KPTI reported a net increase in cash and equivalents of $30.3 million.
  • Investment sales provided some support: The company generated $3.2 million from sale and/or maturity of investments in Q1 2026.
  • Operating losses remain large: Q1 2026 operating loss was $26.8 million, reflecting an ongoing gap between revenue and spending.
  • Expense base is still elevated: SG&A of $26.7 million and R&D of $33.8 million continue to pressure profitability.
  • Shareholder dilution is a real risk: The company relied on equity issuance to strengthen liquidity, which can dilute existing investors.
  • Balance sheet remains leveraged: Total liabilities were $397.1 million versus negative common equity of $265.6 million in Q1 2026.

Looking at the broader trend, KPTI has made progress on revenue stability, but it is still operating with negative equity, substantial debt, and persistent operating losses. The latest quarter suggests the company can still access capital, which helps near-term survivability, but investors should continue to watch whether revenue growth can eventually outpace the heavy expense structure.

Bottom line: KPTI’s latest quarter was better on revenue and liquidity, but the company remains financially fragile and dependent on outside funding to support operations.

07/25/26 08:55 PM ETAI Generated. May Contain Errors.

Karyopharm Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Karyopharm Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Karyopharm Therapeutics' net income appears to be on an upward trend, with a most recent value of -$196.04 million in 2025, rising from -$75.78 million in 2014. The previous period was -$76.42 million in 2024. See where experts think Karyopharm Therapeutics is headed by visiting Karyopharm Therapeutics' forecast page.

Karyopharm Therapeutics' total operating income in 2025 was -$90.71 million, based on the following breakdown:
  • Total Gross Profit: $140.12 million
  • Total Operating Expenses: $230.83 million

Over the last 10 years, Karyopharm Therapeutics' total revenue changed from $229 thousand in 2014 to $146.07 million in 2025, a change of 63,684.7%.

Karyopharm Therapeutics' total liabilities were at $401.34 million at the end of 2025, a 14.5% increase from 2024, and a 2,863.5% increase since 2014.

In the past 10 years, Karyopharm Therapeutics' cash and equivalents has ranged from $49.66 million in 2016 to $190.46 million in 2021, and is currently $60.54 million as of their latest financial filing in 2025.

Over the last 10 years, Karyopharm Therapeutics' book value per share changed from 5.55 in 2015 to -0.02 in 2025, a change of -100.3%.


Related Companies

Financial statements for NASDAQ:KPTI last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel